Materialise N.V. (MTLS) Stock

About Materialise N.V.

Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.

Materialise N.V. is headquartered in BE.

Materialise N.V. (MTLS) stock trades at $6.68 with a market capitalization of $391.15M. The stock is valued at a price-to-earnings (P/E) ratio of 33.24, price-to-book of 1.34, price-to-sales of 1.27. Over the past 52 weeks the stock has ranged between $4.78 and $7.50, and currently trades 10.9% below its 52-week high.

On profitability, Materialise N.V. generates a return on equity (ROE) of 4.13%, return on capital employed of 3.22%, an operating margin of 3.91%, a net profit margin of 3.76%.

Official website: www.materialise.com

Materialise N.V. by the numbers, 2016–2025

Between 2016 and 2025 Materialise N.V. reported revenue of $114.0M rising to $257.0M, a change of +125.4% across 10 years. Compounded, revenue has grown 8.6% a year over five years, 3.5% over three, -3.8% over the last twelve months. Net profit rose to $7.0M.

Operating margin went from 0.1% in 2016 to 1.9% in 2025, a gain of 1.8 percentage points. The most recent net margin is 3.76%. On a trailing twelve-month basis to Mar '26, revenue is $268.0M and net profit $10.0M.

Borrowings rose from $34.0M to $66.0M, cash on hand is $133.0M, cash from operations was $23.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 3.1% over five years, and was 2.8% in the most recent year.

The share price itself has compounded at -21.3% a year over five years, -8.9% over three, 16.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Materialise N.V. (MTLS) — frequently asked questions